Eli Lilly and Company broke ground on Thursday, November 12, on a $3.5 billion manufacturing facility in Fogelsville, Pennsylvania, in the Lehigh Valley, to make injectable medicines including the investigational obesity treatment retatrutide.
The approximately 925,000-square-foot facility is part of Lilly's $50 billion push to expand medicine production in the United States. It is the 10th new U.S. manufacturing site the company has announced since 2020 and one of four among them dedicated to injectable medicines and devices. The site is expected to be operational by 2031 and to create 850 high-wage jobs — engineers, scientists, operations personnel and lab technicians — along with about 2,000 construction jobs. Lilly is already hiring in the Lehigh Valley, and the site is targeting LEED Gold certification.
Retatrutide is a first-in-class investigational triple hormone receptor agonist being studied in Phase 3 clinical trials for obesity, type 2 diabetes and other conditions. It is an investigational molecule that cannot legally be sold or marketed for human use, and Lilly plans to submit a Biologics License Application to the Food and Drug Administration in the first quarter of 2027.
Pennsylvania Gov. Josh Shapiro called the project the largest life-science investment in Pennsylvania history. The state pledged up to $100 million in economic-development incentives, including tax credits, grants and workforce-training funds, to secure the investment. Sen. Dave McCormick also credited the project. Lilly chair and chief executive David A. Ricks said the investment would let the company produce medicines in Pennsylvania for patients nearby and around the world.